621 related articles for article (PubMed ID: 17671215)
21. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
22. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
[TBL] [Abstract][Full Text] [Related]
23. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
[TBL] [Abstract][Full Text] [Related]
24. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
26. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
28. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
Wang S; Li H; Ye C; Lin P; Li B; Zhang W; Sun L; Wang Z; Xue D; Teng W; Zhou X; Lin N; Ye Z
Front Immunol; 2018; 9():377. PubMed ID: 29535738
[TBL] [Abstract][Full Text] [Related]
29. TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism.
Duault C; Franchini DM; Familliades J; Cayrol C; Roga S; Girard JP; Fournié JJ; Poupot M
J Immunol; 2016 Jan; 196(1):493-502. PubMed ID: 26608919
[TBL] [Abstract][Full Text] [Related]
30. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
Li Z; Peng H; Xu Q; Ye Z
J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
[TBL] [Abstract][Full Text] [Related]
31. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.
Santini D; Martini F; Fratto ME; Galluzzo S; Vincenzi B; Agrati C; Turchi F; Piacentini P; Rocci L; Manavalan JS; Tonini G; Poccia F
Cancer Immunol Immunother; 2009 Jan; 58(1):31-8. PubMed ID: 18458903
[TBL] [Abstract][Full Text] [Related]
32. Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of γδ T cells.
Takimoto R; Suzawa T; Yamada A; Sasa K; Miyamoto Y; Yoshimura K; Sasama Y; Tanaka M; Kinoshita M; Ikezaki K; Ichikawa M; Yamamoto M; Shirota T; Kamijo R
Immunology; 2021 Mar; 162(3):306-313. PubMed ID: 33131052
[TBL] [Abstract][Full Text] [Related]
33. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
Fiore F; Castella B; Nuschak B; Bertieri R; Mariani S; Bruno B; Pantaleoni F; Foglietta M; Boccadoro M; Massaia M
Blood; 2007 Aug; 110(3):921-7. PubMed ID: 17403919
[TBL] [Abstract][Full Text] [Related]
34. Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.
Welton JL; Morgan MP; Martí S; Stone MD; Moser B; Sewell AK; Turton J; Eberl M
J Bone Miner Res; 2013 Mar; 28(3):464-71. PubMed ID: 23074158
[TBL] [Abstract][Full Text] [Related]
35. Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
Izumi H; Yamasaki A; Takeda K; Kodani M; Touge H; Tanaka N; Yanai M; Ueda Y; Sakamoto T; Nishii-Ito S; Makino H; Yamaguchi K; Igishi T; Shimizu E
Lung Cancer; 2018 Aug; 122():200-205. PubMed ID: 30032832
[TBL] [Abstract][Full Text] [Related]
36. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
[TBL] [Abstract][Full Text] [Related]
37. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
38. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells.
Ko Y; Jeong YH; Lee JA
Cells; 2022 Jul; 11(14):. PubMed ID: 35883606
[TBL] [Abstract][Full Text] [Related]
40. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
